Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares Russell 2000 ETF (IWM) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

IWM trades at $302.3, up 0.77% with a bullish technical outlook supported by moving averages, though RSI suggests mild overbought conditions. The ETF, tracking the Russell 2000 small-cap index, benefits from institutional favor due to deep liquidity and options markets. Small caps are outperforming large caps year-to-date, with the Russell 2000 up approximately 20% as of July 17, 2026 (24/7 Wall Street).

Outlook remains positive for small-cap exposure amid broadening market rally, but risks include higher volatility and economic sensitivity. Investors gain diversified small-cap access, yet should monitor valuation gaps versus alternatives and interest rate impacts highlighted by Goldman Sachs on July 7, 2026.